Telix Reports 56% Revenue Surge to $803.8M and $5.3M FY25 Loss
Telix reported a fiscal 2025 loss before income tax of $5.3 million versus a $38.0 million profit a year earlier, with adjusted EBITDA falling to $39.5 million from $66.9 million. Revenue surged 56% to $803.8 million and forecasts FY26 revenue of $950 million to $970 million, while management will present at Oppenheimer and TD Cowen conferences.
1. FY25 Financial Results
Telix reported a loss before income tax of $5.3 million for fiscal 2025, reversing a $38.0 million profit in the prior year, with adjusted EBITDA declining to $39.5 million from $66.9 million.
2. Revenue Growth Drivers
Total revenue rose 56% year-over-year to $803.8 million, driven by a 22% increase in Precision Medicine sales fueled by higher Illuccix volumes and the successful U.S. launch of Gozellix.
3. FY26 Revenue Outlook
The company projects group revenue will range between $950 million and $970 million for fiscal 2026, reflecting expectations of continued uptake of its therapeutic and diagnostic radiopharmaceutical products.
4. Conference Participation
Managing Director Dr. Christian Behrenbruch will take part in a fireside chat at the Oppenheimer Healthcare Life Sciences Conference on February 26, and CEO of Precision Medicine Kevin Richardson will present at the TD Cowen Healthcare Conference on March 2, both via live webcast.